Fangsheng Pharmaceutical(SH:603998) 智通财经网·2025-10-09 08:22Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has signed a technology transfer agreement with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream," which includes ownership of the drug's prescription, production process, technical secrets, and related patents and data [1] Group 1: Strategic Development - The company aims to become a health industry group centered on innovative traditional Chinese medicine, continuously increasing R&D investment while also acquiring products with development potential to enrich its product pipeline [1] - The acquisition of the marketing authorization will effectively expand the company's dermatological drug category, potentially providing new profit growth points through brand empowerment [1] Group 2: Market Positioning - This acquisition aligns with the company's development strategy, facilitating industry chain integration and expansion, thereby enhancing the company's market competitiveness [1]